EPISODE · May 17, 2022 · 15 MIN
NFLC: Alicia Algeciras, Ph.D.
from Answers from the Lab · host Mayo Clinic Laboratories
(00:32) Could you let our listeners know a bit about your role and background at Mayo Clinic?(01:23) Is there a lot of information sharing between our neurology clinicians and the Alzheimer’s Disease Research Center when it comes to test development?(01:50) Can you give us a brief overview of the test?(03:17) Is a cerebral spinal fluid test for NFLC already on the market?(04:41) How has Mayo Clinic been able to launch this test in blood? (05:49) What is a laboratory developed test, and what does it mean for physicians?(07:00) Do we have a high degree of confidence that physicians will get an actionable result from this blood test?(07:45) How will Mayo Clinic Laboratories help physicians interpret the test results?(09:15) For which patients is this test most appropriate?(10:59) How might patients benefit from this test?(11:46) How can this test help physicians to know which treatment path to pursue?(12:33) How else might this test benefit patients?(13:49) What about this test excites you most?
Embed this episode
What this episode covers
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions, including Alzheimer’s disease. The new assay can guide physicians’ treatment pathways while avoiding the need for more-invasive testing of cerebral spinal fluid.
NOW PLAYING
NFLC: Alicia Algeciras, Ph.D.
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.